ArticleCurrent addiction reports2025
Medications for OUD: Extended-Release Naltrexone.
Article in Current addiction reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Purpose of Review: Opioid use disorder (OUD) is a chronic, relapsing illness associated with significant morbidity and mortality. Extended-release naltrexone (XR-NTX) is an evidence-based pharmacotherapeutic agent for the treatment of OUD. This review aims at reviewing the extant literature support XR-NTX, its limitations, and providing directions for future research. Recent Findings: XR-NTX has been shown to be comparable to treatment with buprenorphine in head-to-head randomized controlled trials. XR-NTX has demonstrated clinical efficacy in several vulnerable populations with OUD including adolescents, criminal justice offenders, and patients infected with human immunodeficiency virus (HIV). XR-NTX has demonstrated efficacy for other substance use disorders including alcohol use disorder (AUD) and, when combined with bupropion, methamphetamine use disorder. Challenges to treatment include managing opioid withdrawal symptoms during XR-NTX induction as well relapse and overdose upon treatment discontinuation. Summary: XR-NTX is a first-line pharmacotherapeutic option when treating opioid use disorder with demonstrated efficacy; challenges include supporting the patient during withdrawal to facilitate successful induction and encouraging compliance to mitigate risks of relapse and overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.